헬스케어 임상시험수탁기관 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 서비스별, 치료영역별, 분자별, 지역별, 부문 예측(2025-2030년)

Healthcare Contract Research Organization Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-clinical, And Clinical), By Service, By Therapeutic Area, By Molecule, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,632,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,083,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,985,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

헬스케어 임상시험수탁기관 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 헬스케어 임상시험수탁기관 시장 규모는 2030년까지 806억 1,000만 달러에 이를 것으로 추정되며, 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 7.0%로 성장할 것으로 예측됩니다.

의약품 개발 비용 증가는 예측 기간 동안 시장 수요를 촉진할 것으로 예상됩니다. 또한 임상시험 비용 상승과 환자 모집과 관련된 과제로 인해 바이오의약품 기업은 비용 절감과 신속한 환자 모집을 위해 중동유럽, 아시아태평양, 라틴아메리카, 중동 등의 지역으로 눈을 돌리고 있습니다.

게다가 업계 각사에 대한 엄격한 스케줄 준수에 대한 압력 증가로 연구 활동을 CRO(수탁 연구 기관)에 아웃소싱하는 수요가 높아지고 있습니다. 일부 정부 기관은 필요한 인프라와 전문 지식으로 임상시험을 실시하고 비용과 일정을 최소화 할 수 있도록 임상시험 활동을 아웃소싱합니다.

CRO 시장은 팬데믹(세계적 유행)의 영향으로 임상시험 실시 시설이 폐쇄되는 등 일시적인 영향을 받았습니다. 그러나 치료에 대한 큰 수요로 인해 바이러스의 확산을 피하기 위해 일정한 조치와 예방 조치를 취한 후 임상시험 사이트가 재개되었습니다. 또한, 코로나바이러스에 대한 백신의 발견에 세계적으로 초점이 맞추어져 있는 것은 COVID-19에 대한 백신 및 약물의 개발에 큰 영향을 미칩니다. 이것은 시장에 긍정적인 영향을 미칠 것으로 예상됩니다.

지난 5년간 M&A 건수가 크게 증가했습니다. 2016년 이후 2023년까지 여러 대형 합병을 볼 수 있었습니다. 게다가 2022년 3월에는 M&B Sciences Inc.가 Clara Health를 인수했고 M&B Sciences의 디지털 기술을 기반으로 한 임상시험에 대한 접근성을 확대한 것처럼 대형거래 추세는 2021년 이후 활발해지고 있는 것으로 보입니다. 게다가 2021년 12월에는 Thermo Fisher가 의약품 서비스 대기업 PPD의 인수를 발표했고, 2021년 2월에는 ICON plc가 PRA Health Sciences의 인수를 발표했습니다. 바이오 의약품 및 제약 기업의 서비스 영역에서 사용되는 분석 기술 및 소프트웨어 솔루션 주변에서는 통합 시대가 도래하고 있습니다. 따라서 앞서 언급한 요인이 시장 성장을 뒷받침했습니다.

헬스케어 임상시험수탁기관 시장 보고서 하이라이트

• 유형별로는 임상 분야가 2024년 세계의 헬스케어 CRO 시장을 독점하여 76.2%의 최대 점유율을 차지했습니다. 이는 임상 분야가 인간을 대상으로 한 연구를 포함한 네 가지 정교한 단계로 구성되어 있기 때문입니다. 새로운 치료에 대한 큰 수요가 이 부문의 성장에 더욱 기여하고 있습니다.
• 서비스 중 임상 모니터링 분야는 2024년 시장 점유율에서 19.91%로 최대였습니다.
• 북미는 2024년에 45.50%로 큰 시장 점유율을 차지했는데, 이는 연구 활동에 수익의 대부분을 투자하는 세계 기업이 여러 개 존재하기 때문입니다.
• 아시아태평양의 건강 관리 CRO 시장은 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 중국, 일본, 인도는 질병의 만연률이 높기 때문에 의약품 수탁 연구기관 시장의 현저한 성장이 예측됩니다. 중국, 일본, 인도는 높은 질병 유병률로 의약품 위탁 연구 기관 시장에서 놀라운 성장을 보일 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 헬스케어 임상시험수탁기관(CRO) 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 보조 시장 전망
• 시장 역학
  • 시장 드라이버 분석
  • 시장 성장 억제요인 분석
• 기술의 진보
  • AI와 디지털 기술의 통합
• 스폰서에 의한 R&D 투자의 관점
• 임상시험량 분석, 2024년
  • 임상시험의 총수 지역별(2024년)
  • 임상시험의 총수 페이즈별(2024년)
  • 임상시험의 총수 연구 디자인별(2024년)
  • 임상시험의 총수 주요 치료 영역별(2024년)
• 시장 분석 도구
  • Porter's Five Forces 분석
  • SWOT 분석에 의한 PESTEL
  • COVID-19의 영향 분석

제4장 헬스케어 임상시험수탁기관(CRO) 시장 : 유형 추정 및 동향 분석

• 부문 대시보드
• 세계의 헬스케어 임상시험수탁기관(CRO) 시장 변동 분석
• 세계의 헬스케어 임상시험수탁기관(CRO) 시장 규모와 동향 분석, 유형별(2018-2030년)
• 창약
  • 신약 헬스케어 임상시험수탁기관 시장
  • 타겟 검증
  • 리드의 특정
  • 리드 최적화
• 전임상
  • 전임상 헬스케어 임상시험수탁기관 시장
• 임상
  • 임상 헬스케어 임상시험수탁기관 시장
  • Phase I 시험 서비스
  • Phase II 시험 서비스
  • Phase III 시험 서비스
  • Phase IV 시험 서비스

제5장 헬스케어 임상시험수탁기관(CRO) 시장 : 서비스 추정·동향 분석

• 부문 대시보드
• 세계의 헬스케어 임상시험수탁기관(CRO) 시장 변동 분석
• 세계의 헬스케어 임상시험수탁기관(CRO) 시장 규모와 동향 분석, 서비스별(2018-2030년)
• 프로젝트 관리/임상 공급 관리
  • 프로젝트관리/임상공급관리 헬스케어 임상시험수탁기관 시장
• 데이터 관리
  • 데이터 관리 헬스케어 임상시험수탁기관 시장
• 규제/의료 관련
  • 규제/의료업 헬스케어 임상시험수탁기관 시장
• 메디컬 라이팅
  • 메디컬 라이팅 헬스케어 임상시험수탁기관 시장
• 임상 모니터링
  • 임상 모니터링 헬스케어 임상시험수탁기관 시장
• 품질관리/보증
  • 품질관리/보증 헬스케어 임상시험수탁기관 시장
• 생물통계학
  • 바이오 통계 헬스케어 임상시험수탁기관 시장
• 연구자 지불
  • 연구자 지불 헬스케어 임상시험수탁기관 시장
• 연구실
  • 연구실 헬스케어 임상시험수탁기관 시장
  • 무균시험
  • 용기/폐쇄시험
  • 추출물 및 침출성 시험
  • 환경 모니터링
  • 소독제의 효능에 관한 연구
  • 기타
• 환자와 시설의 모집
  • 환자 및 시설 모집 헬스케어 임상시험수탁기관 시장
• 기술
  • 테크놀로지 헬스케어 임상시험수탁기관 시장
• 기타
  • 기타 헬스케어 임상시험수탁기관 시장

제6장 헬스케어 임상시험수탁기관(CRO) 시장 : 치료 영역의 추정·동향 분석

• 부문 대시보드
• 세계의 헬스케어 임상시험수탁기관(CRO) 시장 변동 분석
• 세계의 헬스케어 임상시험수탁기관(CRO) 시장 규모와 동향 분석, 치료영역별(2018-2030년)
• 종양학
• CNS 장애
• 전염병
• 면역 장애
• 심혈관 질환
• 호흡기 질환
• 당뇨병
• 안과
• 통증 관리
• 기타

제7장 헬스케어 임상시험수탁기관(CRO) 시장 : 분자 추정·동향 분석

• 부문 대시보드
• 세계의 헬스케어 임상시험수탁기관(CRO) 시장 변동 분석
• 세계의 헬스케어 임상시험수탁기관(CRO) 시장 규모와 동향 분석, 분자별(2018-2030년)
• 의약품
  • 의약품 헬스케어 임상시험수탁기관 시장
  • 소분자
  • 생물학적 제형
• 의료기기
  • 의료기기 헬스케어 임상시험수탁기관 시장

제8장 헬스케어 임상시험수탁기관(CRO) 시장 : 지역 추정·동향 분석

• 지역 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 동향 분석(2018-2030년) :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
  • 스위스
  • 벨기에
  • 네덜란드
  • 오스트리아
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 태국
  • 대만
  • 인도네시아
  • 말레이시아
  • 싱가포르
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 콜롬비아
  • 칠레
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트
  • 이집트
  • 이스라엘

제9장 경쟁 구도

• 시장 진출기업의 분류
  • 마켓 리더
  • 신흥기업
• 경쟁 시장 점유율/평가 분석(2024년)
• 기업 프로파일
  • ICON Plc
  • Charles River Laboratories
  • Syneos Health
  • IQVIA Inc.
  • GVK Biosciences Private Limited(Aragen)
  • LabCorp
  • Parexel International Corporation
  • WuXi AppTec
  • Thermo Fisher Scientific Inc.
  • CTI Clinical Trial &Consulting
  • PSI
  • Medpace
  • Ergomed
  • Worldwide Clinical Trials
  • Medidata Solutions, Inc.
  • Pharmaron GMBH
  • SGS SA
  • KCR SA
  • Advanced Clinical Research Services, LLC.
  • Pharm-Olam, LLC(Allucent)

KTH

영문 목차

영문목차

Healthcare Contract Research Organization Market Growth & Trends:

The global healthcare contract research organization market size is estimated to reach USD 80.61 billion by 2030, registering to grow at a CAGR of 7.0% from 2025 to 2030 according to a new report by Grand View Research, Inc. The increasing cost of drug development is expected to drive market demand over the forecast period. Also, rising clinical trials cost and challenges pertaining to patient recruitment have led biopharmaceutical companies to turn to regions like Central and Eastern Europe, Asia Pacific, Latin America, and the Middle East for cost savings and quick patient recruitment.

In addition, growing pressure on industry players to follow stringent timelines has increased the demand for outsourcing research activities to contract research organizations (CROs). Some government organizations are also outsourcing their clinical trial activities so that they can carry out clinical trials with the required infrastructure and expertise and minimize their cost and timelines.

The CRO market was temporarily affected by the ongoing pandemic, as it led to the closure of clinical trial sites. However, owing to the significant demand for treatments, the clinical trial sites were reopened with certain measures and precautions to avoid the spread of the virus. Moreover, the worldwide focus on finding a vaccine against coronavirus has had a significant impact on the development of vaccines & drugs for COVID-19. This is expected to have a positive impact on the market.

Over the past 5 years, the number of mergers and acquisitions significantly increased. Several large mergers have been witnessed since 2016 till 2023. Moreover, the trend of large transactions seems to be picking up since 2021, as in March 2022, M&B Sciences Inc, acquired Clara Health, which expanded M&B Sciences' access to digital technology-based clinical trials. Moreover, in December 2021, Thermo Fisher announced the acquisition of pharmaceutical services giant PPD, and in February 2021, ICON plc announced the acquisition of PRA Health Sciences. An era of consolidation has been witnessed around analytical technologies and software solutions used in the biopharmaceutical and pharmaceutical companies' services space. Hence, the aforementioned factors supported the market's growth.

Healthcare Contract Research Organization Market Report Highlights:

• Based on type, the clinical segment has dominated the global healthcare CRO market in 2024, with the largest share of 76.2% owing to the fact that it comprises four elaborate phases, including human subjects. The significant demand for new treatments has further contributed to the growth of the segment.
• Among services, the clinical monitoring segment was the largest in terms of market share at 19.91% in 2024.
• North America held a significant market share of 45.50% in 2024 due to the presence of several global players who invest a major part of their revenue in research activities.
• The healthcare Contract Research Organizations market in Asia Pacific is expected to grow at the fastest CAGR over the forecast period.
• China, Japan, and India are projected to witness tremendous growth in the contract research organization market owing to high disease prevalence. China, Japan, and India are projected to witness tremendous growth in the contract research organization market owing to high disease prevalence.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
  • 1.5.1. Region Wise Market: Base Estimates
  • 1.5.2. Global Market: CAGR Calculation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis (Model 1)
  • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
  • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.6.4. Bottom-Up Approach (Model 4)
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Healthcare Contract Research Organizations (CRO) Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Rate of Clinical Research To Boost Demand For Outsourcing Services
    • 3.2.1.2. Increasing Adoption Of Advanced Technologies
    • 3.2.1.3. Increasing Mergers and Collaborations
    • 3.2.1.4. Increasing Demand For Outsourcing Services Across The Developing Economies
    • 3.2.1.5. Patent Cliff
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Quality issues of CRO services
    • 3.2.2.2. Intellectual property rights issues
• 3.3. Technological Advancements
  • 3.3.1. Integration of AI and digital technologies
• 3.4. R&D Investment Perspective, by Sponsors
• 3.5. Clinical Trials Volume Analysis, 2024
  • 3.5.1. Total Number of Clinical Trials, by Region (2024)
  • 3.5.2. Total Number of Clinical Trials, by Phase (2024)
  • 3.5.3. Total Number of Clinical Trials, by Study Design (2024)
  • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Healthcare Contract Research Organizations (CRO) Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
• 4.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Type, 2018 - 2030 (USD Million)
• 4.4. Drug Discovery
  • 4.4.1. Drug Discovery Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.4.2. Target Validation
    • 4.4.2.1. Target Validation Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.4.3. Lead Identification
    • 4.4.3.1. Lead Identification Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.4.4. Lead Optimization
    • 4.4.4.1. Lead Optimization Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 4.5. Pre-clinical
  • 4.5.1. Pre-clinical Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 4.6. Clinical
  • 4.6.1. Clinical Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.6.2. Phase I Trial Services
    • 4.6.2.1. Phase I Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.6.3. Phase II Trial Services
    • 4.6.3.1. Phase II Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.6.4. Phase III Trial Services
    • 4.6.4.1. Phase III Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.6.5. Phase IV Trial Services
    • 4.6.5.1. Phase IV Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)

Chapter 5. Healthcare Contract Research Organizations (CRO) Market: Service Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
• 5.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Service, 2018 - 2030 (USD Million)
• 5.4. Project Management/Clinical Supply Management
  • 5.4.1. Project Management/Clinical Supply Management Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.5. Data Management
  • 5.5.1. Data Management Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.6. Regulatory/Medical Affairs
  • 5.6.1. Regulatory/Medical Affairs Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.7. Medical Writing
  • 5.7.1. Medical Writing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.8. Clinical Monitoring
  • 5.8.1. Clinical Monitoring Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.9. Quality Management/Assurance
  • 5.9.1. Quality Management/Assurance Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.10. Bio-statistics
  • 5.10.1. Bio-statistics Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.11. Investigator Payments
  • 5.11.1. Investigator Payments Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.12. Laboratory
  • 5.12.1. Laboratory Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.2. Sterility Testing
    • 5.12.2.1. Sterility Testing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.3. Container/Closure Testing
    • 5.12.3.1. Container/Closure Testing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.4. Extractables and Leachable Testing
    • 5.12.4.1. Extractables and Leachable Testing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.5. Environmental Monitoring
    • 5.12.5.1. Environmental Monitoring Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.6. Disinfectant Efficacy Studies
    • 5.12.6.1. Disinfectant Efficacy Studies Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.7. Others
    • 5.12.7.1. Others Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.13. Patient and Site Recruitment
  • 5.13.1. Patient and Site Recruitment Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.14. Technology
  • 5.14.1. Technology Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.15. Others
  • 5.15.1. Others Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)

Chapter 6. Healthcare Contract Research Organizations (CRO) Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
• 6.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. CNS Disorders
  • 6.5.1. CNS Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Infectious Diseases
  • 6.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Immunological Disorders
  • 6.7.1. Immunological Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Cardiovascular Diseases
  • 6.8.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Respiratory Diseases
  • 6.9.1. Respiratory Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.10. Diabetes
  • 6.10.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.11. Ophthalmology
  • 6.11.1. Ophthalmology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.12. Pain Management
  • 6.12.1. Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.13. Others
  • 6.13.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Healthcare Contract Research Organizations (CRO) Market: Molecule Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
• 7.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Molecule, 2018 - 2030 (USD Million)
• 7.4. Pharmaceuticals
  • 7.4.1. Pharmaceuticals Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 7.4.2. Small Molecules
    • 7.4.2.1. Small Molecules Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 7.4.3. Biologics
    • 7.4.3.1. Biologics Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 7.5. Medical Device
  • 7.5.1. Medical Device Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)

Chapter 8. Healthcare Contract Research Organizations (CRO) Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Global Regional Market Snapshot
• 8.3. Market Size & Forecasts Trend Analysis, 2018 - 2030:
• 8.4. North America
  • 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.10. Switzerland
    • 8.5.10.1. Key Country Dynamics
    • 8.5.10.2. Competitive Scenario
    • 8.5.10.3. Regulatory Framework
    • 8.5.10.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.11. Belgium
    • 8.5.11.1. Key Country Dynamics
    • 8.5.11.2. Competitive Scenario
    • 8.5.11.3. Regulatory Framework
    • 8.5.11.4. Belgium Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.12. Netherlands
    • 8.5.12.1. Key Country Dynamics
    • 8.5.12.2. Competitive Scenario
    • 8.5.12.3. Regulatory Framework
    • 8.5.12.4. Netherlands Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.13. Austria
    • 8.5.13.1. Key Country Dynamics
    • 8.5.13.2. Competitive Scenario
    • 8.5.13.3. Regulatory Framework
    • 8.5.13.4. Austria Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Japan
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.8. Taiwan
    • 8.6.8.1. Key Country Dynamics
    • 8.6.8.2. Competitive Scenario
    • 8.6.8.3. Regulatory Framework
    • 8.6.8.4. Taiwan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.9. Indonesia
    • 8.6.9.1. Key Country Dynamics
    • 8.6.9.2. Competitive Scenario
    • 8.6.9.3. Regulatory Framework
    • 8.6.9.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.10. Malaysia
    • 8.6.10.1. Key Country Dynamics
    • 8.6.10.2. Competitive Scenario
    • 8.6.10.3. Regulatory Framework
    • 8.6.10.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.11. Singapore
    • 8.6.11.1. Key Country Dynamics
    • 8.6.11.2. Competitive Scenario
    • 8.6.11.3. Regulatory Framework
    • 8.6.11.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.4. Colombia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.5. Chile
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.6. Egypt
    • 8.8.6.1. Key Country Dynamics
    • 8.8.6.2. Competitive Scenario
    • 8.8.6.3. Regulatory Framework
    • 8.8.6.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.7. Israel
    • 8.8.7.1. Key Country Dynamics
    • 8.8.7.2. Competitive Scenario
    • 8.8.7.3. Regulatory Framework
    • 8.8.7.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Competitive Market Share/Assessment Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. ICON Plc
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Charles River Laboratories
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Syneos Health
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. IQVIA Inc.
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. GVK Biosciences Private Limited (Aragen)
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. LabCorp
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Parexel International Corporation
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. WuXi AppTec
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Thermo Fisher Scientific Inc.
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. CTI Clinical Trial & Consulting
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. PSI
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Medpace
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Ergomed
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Worldwide Clinical Trials
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Medidata Solutions, Inc.
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives
  • 9.3.16. Pharmaron GMBH
    • 9.3.16.1. Company Overview
    • 9.3.16.2. Financial Performance
    • 9.3.16.3. Service Benchmarking
    • 9.3.16.4. Strategic Initiatives
  • 9.3.17. SGS SA
    • 9.3.17.1. Company Overview
    • 9.3.17.2. Financial Performance
    • 9.3.17.3. Service Benchmarking
    • 9.3.17.4. Strategic Initiatives
  • 9.3.18. KCR S.A.
    • 9.3.18.1. Company Overview
    • 9.3.18.2. Financial Performance
    • 9.3.18.3. Service Benchmarking
    • 9.3.18.4. Strategic Initiatives
  • 9.3.19. Advanced Clinical Research Services, LLC.
    • 9.3.19.1. Company Overview
    • 9.3.19.2. Financial Performance
    • 9.3.19.3. Service Benchmarking
    • 9.3.19.4. Strategic Initiatives
  • 9.3.20. Pharm-Olam, LLC (Allucent)
    • 9.3.20.1. Company Overview
    • 9.3.20.2. Financial Performance
    • 9.3.20.3. Service Benchmarking
    • 9.3.20.4. Strategic Initiatives

관련자료